YES! Our flagship study is live on preprint!
- we go from target discovery in 107 young #sarcoma ptns, to preclinical validation, to making a clinical impact🙏 🌟
- ⭐️highlight: FGFR-inhibitor efficacy in PAX3-FOXO1 #rhabdomyosarcoma characterized by FGFR4/FGF8 co-expression⭐️